17/08/2025
ANTIBIOTICS MOST SUSCEPTIBLE TO RESISTANCE
The following is the breakdown of which antibiotics are most prone to resistance, why, and what it means for the future of treatment.
1. Antibiotics that Have the Highest Resistance Rates are Fluoroquinolones (e.g., ciprofloxacin, levofloxacin)
a)Fluoroquinolones exhibit the highest resistance rates among major antibiotic classes. In a comprehensive network meta-analysis, they were significantly more likely to face resistance than carbapenems or aminoglycosides. Comparatively, fluoroquinolones had about a 50% higher risk of resistance relative to meropenem. In serious infections like bloodstream infections, ciprofloxacin resistance ranges from 50% to 77% globally, and averages around 63%.
b)Macrolides (e.g., erythromycin, azithromycin) & Clindamycin
* Among Gram-positive organisms, erythromycin resistance is extremely high around 87.9% followed by clindamycin at 85.3% and azithromycin at 85.1%.
c)Third-Generation Cephalosporins (e.g., ceftriaxone)
* Resistance to third-generation cephalosporins in pathogens like E. coli and Klebsiella pneumoniae is rising sharply:
* For E. coli, median resistance to third-gen cephalosporins is ~42%.
* In typhoid-causing Salmonella Typhi in Gujarat, India, resistance to ceftriaxone and similar antibiotics exceeded 90% in some cases.
d)Beta-Lactams (e.g., penicillins like ampicillin)
* Ampicillin and related penicillins are highly vulnerable due to widespread production of beta-lactamase enzymes like TEM-1 especially in E. coli where up to 90% of resistance stems from this mechanism.
* In ICU-derived isolates (e.g., from Egypt), ampicillin resistance was around 87.3%, ceftazidime resistancesoared to 81.4%, and co-amoxiclav resistance to 83.9%.
2. Antibiotics with Better Durability Against Resistance Carbapenems (e.g., meropenem, imipenem, ertapenem)
* These last-resort antibiotics currently have the lowest resistance rates:
* Meropenem: ~20%
* Imipenem: ~28.6%
* Ertapenem: ~35.2% resistance Frontiers
a)Aminoglycosides (e.g., gentamicin, amikacin)
* Compared to fluoroquinolones, aminoglycosides show moderate resistance:
* Gentamicin: ~26.4%
* Amikacin: ~31.8%
b)Glycopeptides & Oxazolidinones (e.g., vancomycin, linezolid)
* Among Gram-positive infections, vancomycin resistance is minimal (~3.3%), while linezolid resistance is virtually non-existent (0%).
c)Colistin
* Though once highly reliable, colistin resistance is emerging, especially via plasmid-mediated mcr genes, and remains below 10% overall but rising.
3. Some Antibiotics Are More Susceptible to Resistance
1. Widespread misuse and overuse: Fluoroquinolones and broad-spectrum beta-lactams are frequently overprescribed even for viral infections creating high selection pressure.
2. Simple resistance mechanisms:
* Beta-lactamases (e.g., TEM-1, ESBLs) easily inactivate penicillins and cephalosporins.
* Target-site mutations in DNA gyrase/topoisomerase confer rapid fluoroquinolone resistance.
* Efflux pumps and barrier changes reduce intracellular antibiotic concentrations (top tool for organisms like Pseudomonas aeruginosa).
3. Intrinsic resistance mechanisms:
* Species like Pseudomonas aeruginosa carry AMR genes (AmpC, NDM-1, etc.) and naturally low permeability, making broad resistance common.
4. Emergence of last-resort resistance:
* The rise of carbapenemases and colistin-resistance genes (e.g., mcr-1) threatens even the most resilient antibiotic classes.
This Matters is of concern because of the following reasons.
* Treatment implications: Antibiotics like fluoroquinolones are often ineffective today against common infections; reliance on carbapenems and vancomycin is growing.
* Public health risk: Overuse and misuse drive this problem WHO urges use of Access antibiotics, avoiding Watchdrugs unless necessary.
* Urgency for stewardship: Curbing misuse, optimizing prescribing, and investing in surveillance are essential to slowing resistance.
Regards ,
JAKSTAR PHARMA